Tylvalosin (tartrate)

Tylvalosin (Acetylisovaleryltylosin) tartrate is an orally active, broad-spectrum macrolide antibiotic with antimicrobial activity. Tylvalosin tartrate is an antiviral agent useful in studying PRRSV infection. Tylvalosin tartrate induces apoptosis. Tylvalosin tartrate also has anti-inflammatory activity, relieves oxidative stress, and alleviates acute lung injury by inhibiting NF-κB activation[1][2][3][4].

Product Specifications

CAS Number

[63428-13-7]

Product Name Alternative

Acetylisovaleryltylosin (tartrate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Apoptosis; Bacterial; NF-κB

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tylvalosin-tartrate.html

Purity

98.77

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC([C@H](O)[C@@H](O)C(O)=O)=O.O[C@@H]1[C@@H](C)O[C@@H](OC[C@H]([C@@H](CC)OC(C[C@@H](OC(C)=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H](OC(CC(C)C)=O)[C@@](O)(C)C3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@H]4C)=O)/C=C(C)/C=C/C4=O)[C@H](OC)[C@@H]1OC

Molecular Formula

C57H93NO25

Molecular Weight

1192.34

Precautions

H302, H315, H319, H335

References & Citations

[1]Albert Philip Adrian Mockett, et al. Use of tylvalosin as antiviral agent. Patent. WO2008007104.|[2]Zhao Z, et al. Tylvalosin exhibits anti-inflammatory property and attenuates acute lung injury in different models possibly through suppression of NF-κB activation. Biochem Pharmacol. 2014 Jul 1;90 (1) :73-87.|[3]Zhang Q, et al. Tylvalosin Tartrate Improves the Health Status of Swine Herds during Immunization with Porcine Reproductive and Respiratory Syndrome Virus-Inactivated Vaccine. Vet Sci. 2022 Dec 25;10 (1) :12.|[4]Moges R, et al. Anti-Inflammatory Benefits of Antibiotics: Tylvalosin Induces Apoptosis of Porcine Neutrophils and Macrophages, Promotes Efferocytosis, and Inhibits Pro-Inflammatory CXCL-8, IL1α, and LTB4 Production, While Inducing the Release of Pro-Resolving Lipoxin A4 and Resolvin D1. Front Vet Sci. 2018 Apr 11;5:57.